AstraZeneca Plc - Company Profile
Powered by 
All the sales intelligence you need on AstraZeneca Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how AstraZeneca Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with AstraZeneca Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreAstraZeneca Plc (AstraZeneca) is a biopharmaceutical company focused on the research, development, and commercialization of prescription medicines. The company's main activities include developing treatments in the areas of oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals, and vaccines. AstraZeneca sells its products through wholly owned local marketing companies, distributors, and local representative offices to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa, and Australasia. It also collaborates with academia, governments, and other companies to enhance product innovation and the distribution process. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
Headquarters
United Kingdom
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire, CB20AA
Website
www.astrazeneca.com
Telephone
44 203 7495000
No of Employees
96,100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AZN (LON)
Revenue (2024)
$58.7B
18%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
18.1%
(2024 vs 2023)
Market Cap*
$289.2B
Net Profit Margin (2023)
XYZ
0.1%
(2024 vs 2023)
* As of and is in US$
AstraZeneca Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Oncology: | Andexxa/Ondexxya |
| Acalabrutinib | Bevespi Aerosphere |
| Trastuzumab Deruxtecan | Breztri Aerosphere |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In April, the company received approval from the US FDA for Saphnelo Pen to treat adult patients with systemic lupus erythematosus in addition to standard therapy. |
| 2026 | Plans/Strategy | In March, the company announced its plans to build a cell therapy manufacturing and supply base and an innovation centre in Shanghai, China. |
| 2026 | Plans/Strategy | In March, the company announced plans to acquire Abivax. |
Competitor Comparison
| Key Parameters | AstraZeneca Plc | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United States of America | United States of America | United States of America |
| City | Cambridge | New Brunswick | Indianapolis | Rahway | New York City |
| State/Province | Cambridgeshire | New Jersey | Indiana | New Jersey | New York |
| No. of Employees | 96,100 | 138,200 | 50,605 | 75,000 | 75,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pascal Claude Roland Soriot | Chief Executive Officer; Director | Executive Board | 2012 | 67 |
| Aradhana Sarin | Chief Financial Officer; Director | Executive Board | 2021 | 52 |
| Marc Dunoyer | Chief Executive Officer - Alexion; Chief Strategy Officer | Senior Management | 2021 | - |
| Pam P. Cheng | Chief Sustainability Officer; Executive Vice President - Operations and Information Technology | Senior Management | 2023 | - |
| Jeff Pott | Chief Compliance Officer; Chief Human Resources Officer; General Counsel | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer